Tryp Therapeuatics (TRYPF) Coverage Report

Binge eating disorder (BED). According to the National Institutes of Mental Health, the annual prevalence of binge eating disorder in adults is 1.2%, while the lifetime prevalence is 1.6% to 2.8% (Arch Gen Psychiatry. 2011; 68(7): 714). These estimates are similar in Europe as well (J Psychiatr Res. 2009; 43(14): 1125). However, these estimates may be too conservative, as only 3.2% of BED survey respondents who met the DSM-5 criteria had a formal diagnosis (J Clin Psychiatry. 2016; 77(8): e968). BED prevalence is twice as high among females than males. Hypothalamic obesity (HO). Hypothalamic obesity can arise due to the tumor, or an adverse effect of surgery, or from radiotherapy (Front Endocrinol (Lausanne). 2011;3(2):60). Hypothalamic obesity, or intractable weight gain after hypothalamic damage, is one of the most frustrating conditions because there are little-to-no effective remedies as patient suffer from hyperphagia. Attempts to control HO with lifestyle interventions have not been satisfactory. No generally accepted pharmacologic or bariatric therapy for HO in CP has been effective in randomized controlled trials. (Endocrinol Metab Clin North Am. 2020 Sep;49(3):533-552.) A relative common serious adverse outcome following craniopharyngioma surgery is HO, affecting roughly half of surgical patients. With ~1.5 new cases of craniopharyngioma per one million individuals annually, there are ~250 HO patients in the U.S. following craniopharyngioma surgery (Front Endocrinol (Lausanne). 2 011; 2: 60). We estimate there are ~1,500 patients with HO in the U.S. and an equal estimate is likely in Europe. Prader Willi Syndrome (PWS). The incidence of PWS is roughly 1:15,000 births, or ~250 Americans annually. The disease affects both genders equally. The Global PWS Registry includes 2,000 PWS participants from 28 countries, with 75% coming from the U.S. (https://www.fpwr.org/researchtools/registry) . Michael Higgins 212.409.2074 Tryp Therapeutics, Inc. (TRYPF) Page 33